NCT01489787

Study to Evaluate a High Intensity Focused Ultrasound (HIFU) Procedure in Patient With Liver Metastases

A Phase I-II Study to Evaluate, in Patients Operated for a Hepatic Resection of Colorectal Liver Metastases, a High Intensity Focused Ultrasound (HIFU) Procedure: Feasibility, Safety and Accuracy.

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 38 (estimated)
• Sponsor: Centre Leon Berard · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the feasibility, safety and efficacy of High Intensity Focused Ultrasound (HIFU) patients undergoing hepatectomy for colorectal liver metastases. This is a phase I/II study.

Detailed description

Justification and interest of the study: Colorectal liver metastases (CLM) are a major public health issue (16 000 deaths each year in France). To date, complete resection of CLM offers the only potential curative approach. However, only a minority of patients (10 to 20%) is candidates. 5-year survival rates after liver resection are ranged from 20 to 35%. Consequently, alternative locally targeted therapies (radiofrequency, cryotherapy, laser, microwave) have been developed and evaluated. Their use presents many limitations: invasive procedures requiring the intraparenchymal introduction of a probe, impossibility of an accurate monitoring in real-time, small size destruction, time-consuming, high recurrence rate. The development of a non-invasive and more accurate technique combined to surgery is required. High Intensity Focused Ultrasound (HIFU) is a new approach, which enables to generate irreversible cell death through coagulative necrosis in a few seconds. There's no cooling effect of the perfusion because of the shortness of the phenomenon. The surgical team of the Centre Leon Berard, in collaboration with the INSERM U556 one, has undertaken a research program on CLM treatment by HIFU. A new and very powerful device, without the previously named limitations, has been developed. Preclinical studies have revealed the interest, the feasibility and the safety of this process. These results enable considering preceding the program with an early clinical study. Experimental design: Prospective, monocentric phase I/II study evaluating a surgical medical device (SMD). HIFU SMD will be evaluated in clinical conditions, in patients undergoing hepatectomy for colorectal liver metastases. Several HIFU "shootings" (the number will be function of the advancement of the study) will be performed on the liver witch will be resected Objectives and main assessment criteria: 1. st part: Phase I - on the healthy liver to remove. Feasibility 1, Safety 2, Tolerance 3. Success = 1 Ability to perform shootings, supplementary duration of intervention \< 30 minutes; 2 Asepsis, absence of lesion of nearly tissues; 3 Preservation of hemodynamic and respiratory constants. 2. nd part: Phase IIa - on the healthy liver to remove, distant then close to the vascular structures of the liver. Ability of targeting shootings. Success = distance from the epicentre of the HIFU lesion to the mark previously positioned in the liver ≤ 5mm. 3. rd part: Phase IIb - on metastases to remove. Ability, by summation of HIFU lesions, to generate " macro-lesions " including a metastasis and insuring a sufficient safety margin in the healthy tissue. Success = macro-lesion generated in negative margins. Number of patients: 1. st part: The inclusion from 2 to 6 patients is required. The next step (phase II) will depend on: * 1st analysis after 2 patients: * If \< 2 failures: continuation, * If 2 failures: cessation of the study. * 2nd analysis after 6 patients: * If \< 3 failures: continuation (phase II), * If ≥ 3 failures: cessation. 2. nd part: Three patients will be successively included in each of the 2 landings (appendix 1): * If no failure: continuation (2nd landing / Phase IIb), * If ≤ 2 failures: + 3 patients, * If \> 2 failures on 6 patients: cessation, * If ≤ 2 failures on 6 patients: continuation (2nd landing / phase IIb), * If 3 failures: cessation. 3. rd part: * p0 = 0.70 = upper limit of the success rate resulting in the inefficacy of HIFU multi-shootings. * p1 = 0.90 = lower limit of the success rate resulting in the efficacy of HIFU shootings. With a 5% risk of type I error and a 80% power, 28 metastases have to be targeted by HIFU in order to conclude in one-sided situation. Taking into account that an average of 1.5 metastases will be targeted in each patient, 20 patients will be enrolled. 24 observed successes will allow concluding in the reject of H0 to accept H1.

Conditions

• Neoplasm Metastasis

Interventions

Type	Name	Description
PROCEDURE	HIFU	The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient: * One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma. * One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient.
PROCEDURE	HIFU	The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
PROCEDURE	HIFU	Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver. Several metastases can be treated in the same patient

Timeline

• Start date: 2010-03-01
• Primary completion: 2019-10-01
• Completion: 2019-12-01
• First posted: 2011-12-12
• Last updated: 2018-01-29

Locations

1 site across 1 country: France